Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)

INTRODUCTION: To date, there are limited real-world studies published on the use of infliximab-dyyb, a biosimilar to reference product (RP) infliximab approved for the treatment of moderate to severe inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC) in Nort...

Descripción completa

Detalles Bibliográficos
Autores principales: Abraham, Bincy, Eksteen, Bertus, Nedd, Khan, Kale, Hrishikesh, Patel, Dipen, Stephens, Jennifer, Shelbaya, Ahmed, Chambers, Richard, Soonasra, Arif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056488/
https://www.ncbi.nlm.nih.gov/pubmed/35296993
http://dx.doi.org/10.1007/s12325-022-02104-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056488/
https://www.ncbi.nlm.nih.gov/pubmed/35296993
http://dx.doi.org/10.1007/s12325-022-02104-6

Ejemplares similares